4
140
KELLY ET AL.
ANTIMICROB. AGENTS CHEMOTHER.
J. Barbe, and B. Pradines. 2006. Chloroquine resistance reversal agents as
promising antimalarial drugs. Curr. Drug Targets 7:935–948.
8. Hyde, J. E. 2002. Mechanisms of resistance of Plasmodium falciparum to
antimalarial drugs. Microbes Infect. 4:165–174.
9. Ignatushchenko, M. V., R. W. Winter, H. P. Bachinger, D. J. Hinrichs, and
M. K. Riscoe. 1997. Xanthones as antimalarial agents; studies of a possible
mode of action. FEBS Lett. 409:67–73.
0. Ignatushchenko, M. V., R. W. Winter, and M. Riscoe. 2000. Xanthones as
antimalarial agents: stage specificity. Am. J. Trop. Med. Hyg. 62:77–81.
1. Janowsky, A., C. Mah, R. A. Johnson, C. L. Cunningham, T. J. Phillips, J. C.
Crabbe, A. J. Eshleman, and J. K. Belknap. 2001. Mapping genes that
regulate density of dopamine transporters and correlated behaviors in re-
combinant inbred mice. J. Pharmacol. Exp. Ther. 298:634–643.
48. Pukrittayakamee, S., W. Supanaranond, S. Looareesuwan, S. Vanijanonta,
and N. J. White. 1994. Quinine in severe falciparum malaria: evidence of
declining efficacy in Thailand. Trans. R. Soc. Trop. Med. Hyg. 88:324–327.
49. Pukrittayakamee, S., S. Wanwimolruk, K. Stepniewska, A. Jantra, S. Huyakorn,
S. Looareesuwan, and N. J. White. 2003. Quinine pharmacokinetic-pharmaco-
dynamic relationships in uncomplicated falciparum malaria. Antimicrob. Agents
Chemother. 47:3458–3463.
2
2
3
5
0. Riscoe, M., J. X. Kelly, and R. Winter. 2005. Xanthones as antimalarial
agents: discovery, mode of action, and optimization. Curr. Med. Chem.
3
1
2:2539–2549.
5
1. Salama, A., and C. A. Facer. 1990. Desipramine reversal of chloroquine
resistance in wild isolates of Plasmodium falciparum. Lancet 335:164–165.
2. Sangalli, B. C. 1997. Role of the central histaminergic neuronal system in the
CNS toxicity of the first generation H1-antagonists. Prog. Neurobiol. 52:145–
5
3
3
3
2. Jelinek, T., P. Schelbert, T. Loscher, and D. Eichenlaub. 1995. Quinine
resistant falciparum malaria acquired in east Africa. Trop. Med. Parasitol.
1
57.
4
6:38–40.
5
3. Segurado, A. A., S. M. di Santi, and M. Shiroma. 1997. In vivo and in vitro
Plasmodium falciparum resistance to chloroquine, amodiaquine and quinine
in the Brazilian Amazon. Rev. Inst. Med. Trop. Sao Paulo 39:85–90.
4. Smilkstein, M., N. Sriwilaijaroen, J. X. Kelly, P. Wilairat, and M. Riscoe.
3. Kelly, J. X., R. Winter, M. Riscoe, and D. H. Peyton. 2001. A spectroscopic
investigation of the binding interactions between 4,5-dihydroxyxanthone and
heme. J. Inorg. Biochem. 86:617–625.
5
4. Kelly, J. X., R. Winter, D. H. Peyton, D. J. Hinrichs, and M. Riscoe. 2002.
Optimization of xanthones for antimalarial activity: the 3,6-bis-omega-
diethylaminoalkoxyxanthone series. Antimicrob. Agents Chemother. 46:144–
2
004. Simple and inexpensive fluorescence-based technique for high-
throughput antimalarial drug screening. Antimicrob. Agents Chemother.
8:1803–1806.
4
150.
5
5
5. Sowunmi, A., and A. M. Oduola. 1997. Comparative efficacy of chloroquine/
chlorpheniramine combination and mefloquine for the treatment of chloro-
quine-resistant Plasmodium falciparum malaria in Nigerian children. Trans.
R. Soc. Trop. Med. Hyg. 91:689–693.
6. Stahl, S. M. 1984. Regulation of neurotransmitter receptors by desipramine
and other antidepressant drugs: the neurotransmitter receptor hypothesis of
antidepressant action. J. Clin. Psychiatry 45:37–45.
3
5. Kelly, J. X., R. W. Winter, A. Cornea, D. H. Peyton, D. J. Hinrichs, and M.
Riscoe. 2002. The kinetics of uptake and accumulation of 3,6-bis-omega-
diethylamino-amyloxyxanthone by the human malaria parasite Plasmodium
falciparum. Mol. Biochem. Parasitol. 123:47–54.
3
3
6. Krogstad, D. J., P. H. Schlesinger, and I. Y. Gluzman. 1985. Antimalarials
increase vesicle pH in Plasmodium falciparum. J. Cell Biol. 101:2302–2309.
7. Lakshmanan, V., P. G. Bray, D. Verdier-Pinard, D. J. Johnson, P. Horrocks,
R. A. Muhle, G. E. Alakpa, R. H. Hughes, S. A. Ward, D. J. Krogstad, A. B.
Sidhu, and D. A. Fidock. 2005. A critical role for PfCRT K76T in Plasmo-
dium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24:
57. Taylor, D., J. C. Walden, A. H. Robins, and P. J. Smith. 2000. Role of the
neurotransmitter reuptake-blocking activity of antidepressants in reversing
chloroquine resistance in vitro in Plasmodium falciparum. Antimicrob.
Agents Chemother. 44:2689–2692.
2
294–2305.
3
3
4
8. Laufer, M. K., P. C. Thesing, N. D. Eddington, R. Masonga, F. K. Dzinjalamala,
S. L. Takala, T. E. Taylor, and C. V. Plowe. 2006. Return of chloroquine
antimalarial efficacy in Malawi. N. Engl. J. Med. 355:1959–1966.
58. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous
culture. Science 193:673–675.
59. van Schalkwyk, D. A., and T. J. Egan. 2006. Quinoline-resistance reversing
agents for the malaria parasite Plasmodium falciparum. Drug. Resist. Updat.
9:211–226.
60. Waller, K. L., R. A. Muhle, L. M. Ursos, P. Horrocks, D. Verdier-Pinard,
A. B. Sidhu, H. Fujioka, P. D. Roepe, and D. A. Fidock. 2003. Chloroquine
resistance modulated in vitro by expression levels of the Plasmodium falcip-
arum chloroquine resistance transporter. J. Biol. Chem. 278:33593–33601.
9. Martin, S. K., A. M. Oduola, and W. K. Milhous. 1987. Reversal of chloro-
quine resistance in Plasmodium falciparum by verapamil. Science 235:899–
9
01.
0. Miki, A., K. Tanabe, T. Nakayama, C. Kiryon, and K. Ohsawa. 1992. Plas-
modium chabaudi: association of reversal of chloroquine resistance with
increased accumulation of chloroquine in resistant parasites. Exp. Parasitol.
7
4:134–142.
6
1. Warhurst, D. C. 2003. Polymorphism in the Plasmodium falciparum chloro-
quine-resistance transporter protein links verapamil enhancement of chlo-
roquine sensitivity with the clinical efficacy of amodiaquine. Malar. J. 2:31.
2. Warhurst, D. C., J. C. Craig, and I. S. Adagu. 2002. Lysosomes and drug
resistance in malaria. Lancet 360:1527–1529.
4
4
1. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts
between them. J. Antimicrob Chemother. 52:1.
2. Oduola, A. M., A. Sowunmi, W. K. Milhous, T. G. Brewer, D. E. Kyle, L.
Gerena, R. N. Rossan, L. A. Salako, and B. G. Schuster. 1998. In vitro and in
vivo reversal of chloroquine resistance in Plasmodium falciparum with
promethazine. Am. J. Trop. Med. Hyg. 58:625–629.
6
6
3. Wellems, T. E., and C. V. Plowe. 2001. Chloroquine-resistant malaria. J. In-
fect. Dis. 184:770–776.
4
3. Oduola, O. O., T. C. Happi, G. O. Gbotosho, O. A. Ogundahunsi, C. O.
Falade, D. O. Akinboye, A. Sowunmi, and A. M. Oduola. 2004. Plasmodium
berghei: efficacy and safety of combinations of chloroquine and promethazine
in chloroquine resistant infections in gravid mice. Afr. J. Med. Med. Sci.
6
6
4. WHO. 2005. World malaria report 2005. WHO, Geneva, Switzerland.
5. Winter, R. W., M. Ignatushchenko, O. A. Ogundahunsi, K. A. Cornell, A. M.
Oduola, D. J. Hinrichs, and M. K. Riscoe. 1997. Potentiation of an antima-
larial oxidant drug. Antimicrob. Agents Chemother. 41:1449–1454.
6. Winter, R. W., J. X. Kelly, M. J. Smilkstein, R. Dodean, G. C. Bagby, R. K.
Rathbun, J. I. Levin, D. Hinrichs, and M. K. Riscoe. 2006. Evaluation and
lead optimization of anti-malarial acridones. Exp. Parasitol. 114:47–56.
7. Wongsrichanalai, C., A. L. Pickard, W. H. Wernsdorfer, and S. R. Meshnick.
3
3:77–81.
6
6
4
4
4. Olliaro, P. 2001. Mode of action and mechanisms of resistance for anti-
malarial drugs. Pharmacol. Ther. 89:207–219.
5. O’Neill, P. M., S. A. Ward, N. G. Berry, J. P. Jeyadevan, G. A. Biagini, E.
Asadollaly, B. K. Park, and P. G. Bray. 2006. A medicinal chemistry per-
spective on 4-aminoquinoline antimalarial drugs. Curr. Top. Med. Chem.
2
002. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2:209–218.
6
:479–507.
68. Yayon, A., Z. I. Cabantchik, and H. Ginsburg. 1984. Identification of the
acidic compartment of Plasmodium falciparum-infected human erythrocytes
as the target of the antimalarial drug chloroquine. EMBO J. 3:2695–2700.
69. Zhi-Jun, Y., N. Sriranganathan, T. Vaught, S. K. Arastu, and S. A. Ahmed.
1997. A dye-based lymphocyte proliferation assay that permits multiple im-
munological analyses: mRNA, cytogenetic, apoptosis, and immunopheno-
typing studies. J. Immunol. Methods 210:25–39.
4
6. Peters, W., R. Ekong, B. L. Robinson, D. C. Warhurst, and X. Q. Pan. 1990.
The chemotherapy of rodent malaria. XLV. Reversal of chloroquine resis-
tance in rodent and human Plasmodium by antihistaminic agents. Ann. Trop.
Med. Parasitol. 84:541–551.
4
7. Price, R. N., and F. Nosten. 2001. Drug resistant falciparum malaria: clinical
consequences and strategies for prevention. Drug Resist. Updat. 4:187–196.